March 28, 2019 10:10 AM EDT
Pharma

Months af­ter Imfinzi com­bo flops, As­traZeneca wins NICE en­dorse­ment as lung can­cer monother­a­py

Natalie Grover

Reporter

As­traZeneca’s big bet on a com­bi­na­tion of its check­point in­hibitor Imfinzi and in-house CT­LA-4 drug has proved ex­ceed­ing­ly cost­ly, but the British drug­mak­er has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

A service from the Financial Times